A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

Prostate Cancer Recurrent Clinical Trial

— Python  

Official title:

Title A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04734184
• Other study ID #: 2020-000121-37
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 7, 2020
• Est. completion date: February 2022

Study information

• Verified date: February 2021
• Source: Curium PET France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PYTHON is designed to establish the efficacy and safety of 18F-DCFPyL in comparison with that of 18F-fluorocholine, in patients with first biochemical recurrence (BCR) after initial definitive therapy (prostatectomy, external beam radiotherapy or brachytherapy) for histopathologically confirmed prostate adenocarcinoma per original diagnosis. PET/CT scans will be each interpreted by three independent masked experts who are not otherwise involved in the trial.

Description:

The primary objective is the per-patient detection rate of 18F-DCFPyL in comparison with 18F-Fluorocholine. Secondary objectives include the assessment of the impact on patient treatment management, the per-region detection rate, the sensitivity and specificity on a per-patient and per-region basis, the concordance rate between both tracers, and the safety. The study was initiated in July 2020, and the recruitment of the planned 217 patients has been completed in October 2020. The follow-up phase is ongoing. Typically, as part of the routine care practice, these patients receive appropriate treatment and follow-up. The investigating sites are therefore requested for the period of 7 months after the second tracer injection, to provide any results of subsequent biopsies, imaging studies, clinical findings, PSA measurements, and disease management, if performed in routine practice. Treatment decisions are locally made at the discretion of the referring physician based on all available clinical information, including the non-masked local reports of both PET/CT and any other imaging results. After completion of the study, a consensus will be obtained from a multidisciplinary independent board (truth panel), based on the surrogate standard of reference which will include all the above-mentioned available results. Assessments will be made on a per-region and per-patient basis. The truth panel will consist in 3 independent experts not otherwise involved in the trial. All above information will be sequentially presented to the truth panel experts. The order of presentation of 18F-FCH PET/CT and 18F-DCFPyl PET/CT results will be randomized. The truth panel will have to assess the impact of each PET/CT examination on disease restaging and change in treatment intent, by filling in a patient management questionnaire after review of each PET/CT examination report.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 217
• Est. completion date: February 2022
• Est. primary completion date: May 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male.

2. Age min 18 years.

3. Histopathological proven prostate adenocarcinoma per original diagnosis.

4. First suspected recurrence of prostate cancer based on rising prostate-specific antigen (PSA) after initial curative therapy with radical prostatectomy of PSA = 0.2 ng/mL confirmed by a subsequent PSA value of =0.2 ng/mL or with radiation therapy (external beam or brachytherapy) of PSA > 2 ng/mL above the nadir after therapy regardless of the serum concentration of the nadir.

5. Able and willing to provide informed consent and comply with protocol requirements

6. Patient who can undergo all study procedures per Investigator's point of view

7. Patient with social insurance cover.

Exclusion Criteria:

Patients displaying any of the following criteria will not be included:

1. ECOG > 2

2. History of previous salvage therapies (including salvage radiotherapy or salvage lymph node dissection)

3. History of adjuvant radiotherapy

4. History of cryotherapy, high-intensity focused ultrasound (HIFU)

5. Other active malignant tumour

6. Treatment with Androgen Deprivation Therapy (ADT) in the past 30 days or ongoing

7. Treatment with colchicine in the past 8 days or ongoing

8. Treatment with hematopoietic colony stimulating factors (CSF) in the past 5 days or ongoing

9. Unable to lie supine for imaging

10. Known allergy to investigational or reference products or to any excipients

11. Unable to provide written consent (linguistic or psychological inability)

12. Participation in another clinical study within one month prior to inclusion

13. Uncooperative, in the Investigator's opinion.

14. Subjects deprived of their freedom by administrative or legal decision or who are under guardianship

Related Conditions & MeSH terms

• Prostate Cancer Recurrent
• Prostatic Neoplasms
• Recurrence

Intervention

Diagnostic Test:
• DCFPyL
Single dose injection

Locations

Country	Name	City	State
France	CURIUM PET France	Saint-Beauzire

Sponsors (1)

Lead Sponsor	Collaborator
Curium PET France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to compare per-patient detection rate of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT.		10 weeks